Alpine Immune Sciences' (ALPN) Q1 loss per share was less than expected after operational expenditures were lower than anticipated, Wedbush said Friday in...
...
Alpine Immune Sciences (ALPN) reported a Q4 net loss late Thursday of $0.41 per diluted share, narrowing from a loss of $0.52 a year earlier. Analysts...
...
| Address | 188 East Blaine Street Seattle, Washington 98102 |
| Phone | +1.206.788.4545 |
| Number of Employees | 48 |
| Recent SEC Filing | 05/11/2023 424B5 |
| Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
| President & Head-Research & Development | Stanford L. Peng |
| Finance Director | Thaedra Thullberry |
| Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
| Price Open | $9.90 |
| Previous Close | $9.96 |
| 52 Week Range | $4.82 - 10.95 |
| Market Capitalization | $491.6 M |
| Shares Outstanding | 48.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/10/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.71 |
| Beta vs. S&P 500 | N/A |
| Revenue | $705.0 K |
| Net Profit Margin | -245.92% |
| Return on Equity | -40.29% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
